Comment
Author: Admin | 2025-04-28
For adults with type 2 diabetes as an adjunct to diet and exercise to improve glycemic control Wake up to RYBELSUS® (semaglutide)—the first type 2 diabetes pill in its class (GLP-1 RA)1 How often do you prescribe RYBELSUS® to your T2D patients for glycemic control? Select one to get info that’s relevant to you. GLP-1 RA=glucagon-like peptide-1 receptor agonist; T2D=type 2 diabetes. Wake up to RYBELSUS® (semaglutide)— the first type 2 diabetes pill in its class (GLP-1 RA)1 GLP-1 RA=glucagon-like peptide-1 receptor agonist; T2D=type 2 diabetes. See which patients with T2D may be right for RYBELSUS® Actor portrayals of hypothetical patients Have you identified T2D patients in your care who may be RYBELSUS® READY? Actor portrayals of hypothetical patients Superior A1C reduction vs Jardiance® (empagliflozin) at 26 weeks1 In PIONEER 2, RYBELSUS® went head-to-head against the most prescribed SGLT-2i with mean change in A1C from baseline to 26 weeks as a primary endpoint and mean change in body weight from baseline to 26 weeks as a confirmatory secondary endpoint.1,3,4 A1C=glycated hemoglobin; SGLT-2i=sodium-glucose cotransporter-2 inhibitor. Superior A1C reduction vs Januvia® (sitagliptin) at 26 weeks1 In PIONEER 3, RYBELSUS® went head-to-head against the most prescribed DPP-4i with mean change in A1C from baseline to 26 weeks as a primary endpoint and mean change in body weight from baseline to 26 weeks as a confirmatory secondary endpoint.1,2,4 A1C=glycated hemoglobin; DPP-4i=dipeptidyl peptidase-4 inhibitor. What do these two T2D experts have in common? Both believe in RYBELSUS® as an option to lower blood glucose for appropriate adult patients with T2D. Find out why in the PIONEER Roundtable series. Davida Kruger, NP and Julio Rosenstock, MD received a fee from Novo Nordisk Inc. for their participation in this video series. What do these two T2D experts have in common? Both believe in RYBELSUS® as an option to lower blood glucose for appropriate adult patients with T2D. Find out why in the PIONEER Roundtable series. Davida Kruger, NP and Julio Rosenstock, MD received a fee from Novo Nordisk Inc. for their participation in this video series. What are you waiting for? Learn about our tool that allows you to find a patient’s coverage status and get an estimated prescription cost in minutes. Looking for information about samples and resources? Complete a simple registration to receive the latest product news and education from Novo Nordisk References:RYBELSUS® [package insert]. Plainsboro, NJ: Novo Nordisk Inc; January 2023.Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019;321(15):1466-1480.Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type
Add Comment